Stock Analiz

ABBV vs NVS stock comparison

AbbVie vs. Novartis · data as of November 13, 2026

AbbVie (ABBV) has a market value of about $521.5B, Novartis (NVS) about $306.3B. Over their latest twelve months AbbVie had revenue of $66.0B and Novartis $57.4B.

On our five checks Novartis scores higher: 2.0 out of 5 (weak) against 1.8 (weak).

By area, the stronger company is AbbVie on future growth; Novartis on track record; Novartis on financial health; AbbVie on shareholder returns.

Novartis is cheaper on earnings (P/E 30.7 vs. 50.8), while AbbVie grew revenue faster over five years (5.9% vs. 2.3% a year).

AbbVie leads on 8 of the compared lines and Novartis on 15.

Side by side

ABBVNVS
Size and price
Market cap$521.5B$306.3B
Share price$295.03$160.50
Score
Overall score (of 5)1.82.0
Value00
Future growth10
Track record24
Financial health23
Shareholder returns43
Valuation
P/E (TTM)50.830.7
Forward P/E19.117.0
Price / free cash flow27.621.9
Price / sales7.95.3
EV / EBITDA19.814.4
PEG—2.02
DCF value vs. price−20%−9%
Business
Revenue$66.0B$57.4B
Net income$10.3B$10.0B
Free cash flow$18.9B$14.0B
Net margin15.7%17.5%
Gross margin (5-yr avg.)68.3%76.4%
ROIC (5-yr avg.)15.3%14.1%
Growth
Revenue growth (1 yr)8.6%8.4%
Revenue growth (5 yrs, per year)5.9%2.3%
EPS growth (5 yrs, per year)-2.8%15.2%
Balance sheet and payouts
Net cash (cash minus debt)-$61.5B-$39.3B
Dividend yield2.35%2.95%
Shareholder yield2.5%6.0%
Analysts
Upside to average target+6%−2%
Consensus ratingBuyHold

Highlighted = the better figure on that line. Revenue, net income and free cash flow: ABBV TTM to September 30, 2026, NVS TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, AbbVie or Novartis?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Novartis scores 2.0 out of 5 and AbbVie 1.8; the table shows where each one is stronger.

Is AbbVie cheaper than Novartis?

On trailing earnings, Novartis trades at a P/E of 30.7 and AbbVie at 50.8, so Novartis is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, AbbVie or Novartis?

Over five years AbbVie grew revenue about 5.9% a year and Novartis about 2.3% a year.

Which pays a higher dividend?

AbbVie yields 2.35% and Novartis 2.95%.

Full AbbVie analysis → Full Novartis analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.